About Lipigon

Lipigon is a clinical-stage pharmaceutical company. The company develops drugs for the treatment of diseases caused by disturbances in the body’s handling of fats, so-called lipid-related diseases, where adequate treatment is currently lacking or limited and where there is a significant medical need. Triglycerides, a type of fat found in the blood, play a central role in the company’s research.

The company’s most advanced drug candidate, Lipisense®, is initially focused on lowering triglyceride levels in patients with dangerously high levels. Such a condition can lead to recurring cases of the life-threatening condition acute pancreatitis, an inflammation of the pancreas. In the long term, Lipigon sees opportunities to expand the indications for Lipisense® to include the treatment of high triglycerides in order to reduce the risk of cardiovascular disease or type 2 diabetes.

Read more about Lipisense®

In addition to Lipisense®, Lipigon currently has two other drug development projects.

Lipids

  • Lipids, or fats, are biological materials that are not soluble in water and require other solvents.
  • They are primarily composed of carbon and hydrogen atoms. Fats are energy-rich because their covalent bonds contain a lot of energy.
  • There are different types of fats in the body, including triglycerides, phospholipids, fatty acids, steroids, sterols, waxes, fat-soluble vitamins, and hormones.
  • Lipids have many important functions in the body. They form cell membranes, store energy reserves, act as hormones, provide insulation, and protect internal organs.